Clinical Trial: Early Feasibility Study to Evaluate the Safety and Recommended Dose of the Sarah Nanotechnology System, for Patients With Stage 4 Metastatic Solid Tumors.The Investigational Device Uses Iron Oxide Nanoparticles Together With Non-Ionizing Alternating Magnetic Field to Generate Heat and Destroy Tumors

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07224464) titled 'Early Feasibility Study to Evaluate the Safety and Recommended Dose of the Sarah Nanotechnology System, for Patients With Stage 4 Metastatic Solid Tumors.The Investigational Device Uses Iron Oxide Nanoparticles Together With Non-Ionizing Alternating Magnetic Field to Generate Heat and Destroy Tumors' on Nov. 03.

Brief Summary: This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Eligible participants have stage 4 metastatic solid tumor(s), that is(are) not respondi...